Inflammation Inhibiting Compounds
OwnerThomas LUGERinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of αMSH for inducing tolerance.
Claims12
A medicament for the treatment and/or prevention of an inflammatory disorder selected from the group consisting of enterocolitis, psoriasis, allergic reactions, food allergies, rheumatoid arthritis, multiple sclerosis, asthma, contact allergies, rhinitis, atopic dermatitis, transplant rejection, scleroderma, autoimmune diseases and inflammatory disorder of the blood vessels, said medicament comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-Pro, N-acyl Lys-Pro, C-amide Lys-Pro, C-esters of Lys-Pro, Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr;
- or a pharmaceutically acceptable salt of said compound.
A method for treatment of psoriasis comprising the step of administering to a patient in need of such treatment, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-Pro, N-acyl Lys-Pro, C-amide Lys-Pro, C-esters of Lys-Pro, Lys-(D)Pro-Thr [K(D)PT] (KPT), N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr;
- or a pharmaceutically acceptable salt of said compound, wherein said therapeutically effective amount is in the range from 20 μg/kg of body weight to 10 mg/kg of body weight.
A method for treatment of allergic reactions comprising the step of administering to a patient in need of such treatment, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-Pro, N-acyl Lys-Pro, C-amide Lys-Pro, C-esters of Lys-Pro, Lys-(D)Pro-Thr [K(D)PT] (KPT), N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr;
- or a pharmaceutically acceptable salt of said compound, wherein said therapeutically effective amount is in the range from 20 μg/kg of body weight to 10 mg/kg of body weight.
A method for treatment of psoriasis comprising the step of administering to a patient in need of such treatment, an ointment for topical application, said ointment containing a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-Pro, N-acyl Lys-Pro, C-amide Lys-Pro, C-esters of Lys-Pro, Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr;
- or a pharmaceutically acceptable salt of said compound, wherein said compound is present in said ointment in a concentration of from 1 μM to 1 mM.
Dependencies are inferred from the claim text.